Register Login
Register to leave comments
  • News bot March 22, 2026, 3:11 a.m.

    📋 MOLECULIN BIOTECH, INC. (MBRX) - Financial Results

    Filing Date: 2026-03-19

    Accepted: 2026-03-19 08:35:12

    Event Type: Financial Results

    Event Details:

    MOLECULIN BIOTECH, INC. (MBRX) Reports the reporting period Financial Results MOLECULIN BIOTECH, INC. (MBRX) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: Not disclosed
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 8878
      • targeting glioblastoma and pediatric brain tumors. Moleculin expects several important milestones in the coming months. Summary of Financial Results for the Full Year 2025
      • expected in mid‑2026
      • targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2025 2024 Change ($) Change (%)
    Current Assets Prepaid Expenses Other Current Assets 808.00 916.00 $-108.00 -11.79%
    Current Assets Intangible Assets Net 11.15K 11.15K $0.00 +0.00%
    Current Assets Operating Lease Right Of Use Assets 314.00 424.00 $-110.00 -25.94%
    Operating Expenses Loss From Operations 25.10K 26.64K $-1.54K -5.77%
    Other Income Net Loss 33.56K 26.05K $7.51K +28.84%
    Net Loss Per Share 28.42 189.14 $-160.72 -84.97%
    Prepaid Expenses and Other Current Assets 808.00 916.00 $-108.00 -11.79%
    Accounts Payable 6.85K 5.36K $1.50K +27.90%
    Loss from Operations 25.10K 26.64K $-1.54K -5.77%
    Interest Income 105.00 550.00 $-445.00 -80.91%
    Net Loss 33.56K 26.05K $7.51K +28.84%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: MOLECULIN BIOTECH, INC.
    • Ticker Symbol: MBRX

Search

News categories